Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

t an expanded cohort of patients at the maximum tolerated dose.  The company has cleared a safety review after dosing the 5 mg/kg cohort and has authorization to start enrolling patients at 10 mg/kg.  Top-line results are expected in the second half of 2012.
  • BMN-673 (PARP inhibitor):  BioMarin has two ongoing trials for BMN-673.  In the first quarter of 2011, the company initiated a Phase I/II open-label trial of once daily, orally administered BMN-673 for advanced or recurrent solid tumors.  In July 2011, the company initiated a Phase I, two-arm, open-label, dose escalation study for BMN-673 for the treatment of patients with advanced hematological malignancies.  The primary objective of the studies is to establish the maximum tolerated dose of daily oral BMN-673 and to obtain preliminary efficacy data in an expanded cohort of patients with genetically-defined tumors.  

  • Preclinical Programs

  • BMN-111 for Achondroplasia: Regulatory interactions are underway, and BioMarin expects to initiate a Phase I trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth, for achondroplasia, the most common form of dwarfism.  There are approximately 18,000 to 24,000 patients in the U.S. and Europe, an estimated 25 percent of which could be candidates for treatment with a product like BMN-111.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and six months ended June 30, 2011 and June 30, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
    (Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
    (Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
    Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
    ... , SAN CLEMENTE, Calif., Nov. 17 Three ... ages of two through 12 are extremely, very, or ... according to a survey conducted by Opinion Research Corporation ... research of natural remedies including Sinupret® for Kids, a ...
    ... , DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. ... has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers ... which are going out today, cover orders received through ... for our company - actually shipping a product to ...
    Cached Medicine Technology:Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
    (Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
    (Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
    (Date:7/29/2014)... Dublin, Ireland (PRWEB) July 30, 2014 ... announced the successful completion of a Phase I trial ... Acid (DGLA). , This study was a randomized, placebo-controlled, ... to assess the safety, pharmacokinetics and effect of food ... confirmed the benign safety profile of DGLA following both ...
    (Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
    (Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... this program claims that he cured his condition with the ... to share part of his experience. , He claimed ... and naturally in just 4 days. Since his method turned ... sufferers from all around the world. , The Nasal ...
    Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
    ... HealthDay Reporter , FRIDAY, May 13 (HealthDay News) -- ... to a veterinary clinic near her home in Austin, Texas, when ... like herself," recalled Wong. After running a blood and ... Diabetes is on the rise as America,s cats and dogs grow ...
    ... in the brains of patients with Alzheimer disease collude, resulting ... cells, according to new findings published online in Neurobiology ... pathological forms of two proteins, amyloid beta and tau, which ... patients plaques and tangles may work in tandem ...
    ... News) -- Being well-informed about their disease may lead to ... and other emotions about their condition, according to new research. ... were taking medication to manage the disease, and had symptoms ... and abdomen. The women,s coping styles affected their levels ...
    ... By Dennis Thompson HealthDay Reporter , FRIDAY, May ... the punch line of jokes, prompting chuckles about "mystery meat" ... days, with childhood obesity reaching epidemic proportions in the United ... their kids fit and healthy through proper nutrition. "Five ...
    ... It,s something we just accept: the fact that the older we ... can leave our ,cars in the same parking lot each morning, ... day, it,s a challenge eight hours later to ,recall whether we ... can ,be introduced to new colleagues at a meeting and will ...
    ... May 12 (HealthDay News) -- Representatives for veteran TV ... a facility for surgery to remove a meningioma -- ... on the meninges, the brain,s protective outer membrane. ... monitoring this for years, and a neurosurgeon, Mary decided ...
    Cached Medicine News:Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 2Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 3Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 2Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 3Health News:For Some Women, Knowing About Heart Failure Spurs Worry 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 3Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Brain Surgery for Mary Tyler Moore to Remove Benign Tumor 2
    Used to remove wrinkles from sections and for reorientating embedded tissue....
    ... Plus CO-Oximeter Control (Bayer 800 Series) ... in monitoring the performance of blood ... (Bayer 270 and 800 series) instrumentation. ... on Bayer 800 Rapidlab Series instruments ...
    Prevents formation of microscopic ice crystals and sample distortion caused by slow freezing of hyperosmolar tissue samples in conventional cyrostats....
    Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
    Medicine Products: